Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Nippon Shinyaku Submits Sakigake DMD Drug Viltolarsen in Japan, Could Be Approved by March
Nippon Shinyaku said on September 26 that it has submitted a new drug application in Japan for the oligonucleotide drug viltolarsen, which was granted sakigake fast-track designation, for the treatment of Duchenne muscular dystrophy (DMD). If all goes well, it…
To read the full story
Related Article
- FDA Accepts Nippon Shinyaku’s DMD Drug for Review, Target Date Set for Q3 2020
February 10, 2020
- Nippon Shinyaku Seeks US Approval for DMD Therapy Viltolarsen
October 3, 2019
- MHLW Grants Orphan Status to Nippon Shinyaku’s DMD Med Viltolarsen
August 22, 2019
- Nippon Shinyaku Eyes Conditional Early OK for Sakigake DMD Drug, Daiichi Sankyo Redoing PI/II for Its Antisense
September 12, 2018
BUSINESS
- Takeda Turns the Page to Kim’s “10-Year” Era, Betting on New Drugs and AI
June 26, 2026
- Sangamo Files Chapter 11, Astellas and Lilly Eye Key Assets
June 26, 2026
- Otsuka’s Centanafadine Meets PIII Goal in ADHD Patients with Anxiety
June 26, 2026
- Shionogi Welcomes Government Roadmap’s Focus on Infectious Diseases
June 26, 2026
- Sawai Cleared to Manufacture Nichi-Iko’s Lipitor Generic
June 26, 2026
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…